In Challenging Times, Sanofi’s Viehbacher Explores New Pricing Models In Emerging Markets
This article was originally published in PharmAsia News
In a rare spotlight opportunity, Sanofi CEO Christopher Viehbacher shares his views on emerging markets during a visit to Mumbai.
You may also be interested in...
MUMBAI - French drug maker Sanofi's long search for high-growth OTC brands in India finally materialized as it announced the acquisition of Mumbai-headquartered Universal Medicare Pvt. Ltd.'s nutraceutical businesses
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.